Literature DB >> 22862907

Neutropenic enterocolitis after high-dose chemotherapy and autologous stem cell transplantation: incidence, risk factors, and outcome.

L Gil1, D Poplawski, A Mol, A Nowicki, A Schneider, M Komarnicki.   

Abstract

BACKGROUND: Neutropenic enterocolitis (NE) is a life-threatening complication occurring after intensive chemotherapy; however, no data are available on NE development after hematopoietic stem cell transplantation (SCT). The aim of this study was to determine the incidence, risk factors, and outcome of NE after high-dose chemotherapy and autologous SCT (autoSCT).
METHODS: A total of 297 adult patients who qualified for autoSCT with non-Hodgkin's lymphoma (NHL), Hodgkin's disease, multiple myeloma, and acute myeloid leukemia were analyzed. Patients were conditioned with carmustine, etoposide, cytarabine, melphalan (BEAM); melphalan alone; or busulfan and cyclophosphamide (BuCy2), and transplanted with peripheral blood or bone marrow CD34(+) cells. Diagnosis of NE was established in case of neutropenic fever, abdominal pain or diarrhea, and bowel wall thickening >4 mm on abdominal sonography.
RESULTS: Neutropenic infections occurred in 262 patients (88%). NE was diagnosed in 32 patients (12%), a median +3 (1-5) days after SCT. Bloodstream infections were present in 18 patients, with gram-negative bacteria in 11 patients. All patients were treated conservatively with carbapenems and total parenteral nutrition with bowel rest. The course of disease was complicated by ileus or septic shock in 9 patients, and was fatal for 3 (9.6%) patients. In univariate analysis, the initial diagnosis of NHL (P = 0.017) and conditioning with BEAM (P = 0.043) had prognostic value. In multivariate analysis, only initial diagnosis of NHL (P = 0.017) had prognostic significance.
CONCLUSIONS: NE is a rare but severe complication in patients undergoing autoSCT. Gram-negative bacteria remain the main causative pathogen. Abdominal sonography allows early diagnosis and treatment, effective in most of patients without surgery. In our analysis, NE was seen more often in NHL patients treated with a BEAM regimen.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22862907     DOI: 10.1111/j.1399-3062.2012.00777.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  5 in total

1.  A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.

Authors:  T-F Wang; M A Fiala; A F Cashen; G L Uy; C N Abboud; T Fletcher; N Wu; P Westervelt; J F DiPersio; K E Stockerl-Goldstein; R Vij
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

2.  Neutropenic Enterocolitis as a Complication of Autologous Stem Cell Transplant in Patients With Multiple Myeloma: A Case Series.

Authors:  Nadia Belmoufid; Sanae Daghri; Soukaina Driouich; Anass Nadi; Nouama Bouanani
Journal:  Cureus       Date:  2022-04-25

3.  Evaluation of thromboelastometry parameters as predictive markers for sinusoidal obstruction syndrome in patients undergoing allogeneic stem cell transplantation for acute leukaemia.

Authors:  Joanna Rupa-Matysek; Lidia Gil; Ewelina Wojtasińska; Zuzanna Kanduła; Adam Nowicki; Magdalena Matuszak; Mieczysław Komarnicki
Journal:  Oncotarget       Date:  2017-06-15

4.  [Therapeutic effect of CY-fTBI and BMM conditioning regimen in the process of allo-HSCT treating Ⅲ,Ⅳ non-Hodgkin lymphoma: 15 years analysis of single-center].

Authors:  Ting Sun; Liangding Hu; Min Jiang; Hongmei Ning; Bin Zhang; Jing Ren; Yuhang Li; Botao Li; Jianlin Chen; Fan Yang; Chen Xu; Jun Wang; Xiao Lou; Jiangwei Hu; Hu Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-10

5.  Investigation of typhlitis in bone marrow transplant patients in a stem cell transplant unit.

Authors:  Burak Deveci; George Kublashvili; Saim Yilmaz; Bariş Özcan; Halil Fatih Korkmaz; Olcay Gürsoy; Tayfur Toptaş; Levent Döşemeci; Rabin Saba
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.